Immuron Ltd ADR (IMRN)

$0.96 +0.11 (13.35%)
Market Cap 6.90M
Revenue (ttm) 4.72M
Net Income (ttm) -3.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -71.61%
Debt to Equity Ratio 0.00
Volume 207,700
Avg Vol 26,216
Day's Range N/A - N/A
Shares Out 8.17M
Stochastic %K 82%
Beta 0.84
Analysts Strong Buy
Price Target $5.00

Company Profile

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune su...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9824 5254
Fax: 61 3 9822 7735
Address:
62 Lygon Street, Level 3 Carlton South, Carlton, Australia
t_baggin_u
t_baggin_u Apr. 17 at 10:29 AM
$IMRN https://www.globenewswire.com/news-release/2026/04/17/3276005/37134/en/Immuron-Double-Digit-3Q-Sales-Growth.html
0 · Reply
t_baggin_u
t_baggin_u Apr. 17 at 5:13 AM
$IMRN https://investors.immuron.com.au/announcements/7494849
0 · Reply
DravenHunt
DravenHunt Apr. 13 at 3:10 PM
$IMRN Severe underperformance vs market & peers
0 · Reply
DravenHunt
DravenHunt Apr. 13 at 3:07 PM
$IMRN Extremely weak technical trend..
0 · Reply
UltimateRampageBulls
UltimateRampageBulls Mar. 24 at 10:51 PM
Actually a good group of bulls below, they actually jumped in to some runners early💎 Check them out, Cool free group 👇🔥 Been swinging some $NAK $RZLT $IMRN $ADGM too
0 · Reply
peepthestamp
peepthestamp Mar. 6 at 8:23 PM
$IMRN
0 · Reply
Baseball89
Baseball89 Mar. 3 at 12:32 PM
$EHTH $IMRN keep watch. Profitable yr after yr.
0 · Reply
Baseball89
Baseball89 Feb. 27 at 5:51 PM
$BDSX $NCNA & $IMRN keep watch.Sleeping giant!!!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 27 at 1:58 AM
$IMRN RSI: 57.17, MACD: -0.0454 Vol: 0.07, MA20: 0.78, MA50: 0.87 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Baseball89
Baseball89 Feb. 23 at 11:02 PM
$IMRN This could reach $80-$100 soon. Keep watch.
0 · Reply
Latest News on IMRN
Immuron Double Digit 3Q Sales Growth

Fri, 17 Apr 2026 06:00:00 -0400 - 1 day ago

Immuron Double Digit 3Q Sales Growth

Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target

Thu, 05 Mar 2026 11:05:00 -0500 - 6 weeks ago

Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target

Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference

2026-03-05T11:00:00.000Z - 6 weeks ago

Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference

Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target

Thu, 22 Jan 2026 06:00:00 -0500 - 3 months ago

Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target

Immuron Reports Continued Sales Growth

Mon, 19 Jan 2026 06:00:00 -0500 - 3 months ago

Immuron Reports Continued Sales Growth

Immuron (IMRN) Collaborates on Vaccine Research with US Military Institutes

2025-12-03T11:53:11.000Z - 4 months ago

Immuron (IMRN) Collaborates on Vaccine Research with US Military Institutes

Immuron (IMRN) Secures FDA Approval for Phase 2 Trial of IMM-529

2025-11-05T11:58:49.000Z - 5 months ago

Immuron (IMRN) Secures FDA Approval for Phase 2 Trial of IMM-529

Immuron: FDA Approves IND Application For IMM-529

2025-11-05T11:25:02.000Z - 5 months ago

Immuron: FDA Approves IND Application For IMM-529

Immuron IMM-529 IND approved by FDA

Wed, 05 Nov 2025 06:00:00 -0500 - 5 months ago

Immuron IMM-529 IND approved by FDA

Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target

Fri, 17 Oct 2025 11:07:00 -0400 - 6 months ago

Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target

Immuron Announces Rise In Global Revenue For Q1

2025-10-13T12:54:51.000Z - 6 months ago

Immuron Announces Rise In Global Revenue For Q1

Immuron Q1 FY26 YoY growth

Mon, 13 Oct 2025 06:00:00 -0400 - 6 months ago

Immuron Q1 FY26 YoY growth

Immuron (IMRN) Seeks FDA Green Light for Novel C. diff Treatment

2025-10-08T11:31:48.000Z - 6 months ago

Immuron (IMRN) Seeks FDA Green Light for Novel C. diff Treatment

Why Immuron Is Rising In Pre-market?

2025-10-08T10:16:00.000Z - 6 months ago

Why Immuron Is Rising In Pre-market?

Immuron Submits IMM-529 IND to FDA

Wed, 08 Oct 2025 06:00:00 -0400 - 6 months ago

Immuron Submits IMM-529 IND to FDA

Immuron (IMRN) Updates Shareholders on Key Project Developments

2025-10-02T11:26:44.000Z - 7 months ago

Immuron (IMRN) Updates Shareholders on Key Project Developments

Immuron Letter to Shareholders – Projects Update

Thu, 02 Oct 2025 06:00:00 -0400 - 7 months ago

Immuron Letter to Shareholders – Projects Update

Immuron partners with InvestorHub

Tue, 26 Aug 2025 22:29:00 -0400 - 8 months ago

Immuron partners with InvestorHub

Immuron - FY25 global sales exceed projection, up 49% on prior year

Thu, 17 Jul 2025 06:00:00 -0400 - 9 months ago

Immuron - FY25 global sales exceed projection, up 49% on prior year

Immuron Letter to Shareholders: Projects Update

Fri, 30 May 2025 06:00:00 -0400 - 11 months ago

Immuron Letter to Shareholders: Projects Update

Immuron (IMRN) Achieves Record Sales Milestone

2025-04-11T08:55:40.000Z - 1 year ago

Immuron (IMRN) Achieves Record Sales Milestone

Immuron Travelan® highest sales in history

Thu, 10 Apr 2025 18:00:00 -0400 - 1 year ago

Immuron Travelan® highest sales in history

Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)

Wed, 05 Mar 2025 06:00:00 -0500 - 1 year ago

Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)

Immuron Travelan® continued strong sales growth

Fri, 17 Jan 2025 06:00:00 -0500 - 1 year ago

Immuron Travelan® continued strong sales growth

Immuron Announces New Research Collaboration targeting Antimicrobial Resistance

Wed, 15 Jan 2025 06:00:00 -0500 - 1 year ago

Immuron Announces New Research Collaboration targeting Antimicrobial Resistance

Immuron Announces Travelan® Clinical Trial Update

Tue, 14 Jan 2025 06:00:00 -0500 - 1 year ago

Immuron Announces Travelan® Clinical Trial Update

Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th

Mon, 02 Dec 2024 06:00:00 -0500 - 1 year ago

Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th

Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event

Thu, 21 Nov 2024 18:33:00 -0500 - 1 year ago

Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event

Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event

Mon, 18 Nov 2024 08:30:00 -0500 - 1 year ago

Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event

Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference

Wed, 16 Oct 2024 06:00:00 -0400 - 1 year ago

Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference

Immuron Travelan® continued strong sales growth

Tue, 15 Oct 2024 06:00:00 -0400 - 1 year ago

Immuron Travelan® continued strong sales growth

NMRC Reports Results for Campylobacter Controlled Human Infection Model Study

Fri, 04 Oct 2024 06:30:00 -0400 - 1 year ago

NMRC Reports Results for Campylobacter Controlled Human Infection Model Study

Traveler's Diarrhea Therapeutics Pipeline Market Report 2024 Featuring Immuron, Scandinavian Biopharma, and Sigmoid Pharma

Thu, 19 Sep 2024 09:42:00 -0400 - 1 year ago

Traveler's Diarrhea Therapeutics Pipeline Market Report 2024 Featuring Immuron, Scandinavian Biopharma, and Sigmoid Pharma

Immuron Ltd Webinar Presentation Transcript

2024-09-14T11:17:07.000Z - 1 year ago

Immuron Ltd Webinar Presentation Transcript

Immuron Ltd at Emerging Growth Virtual Conference Transcript

2024-09-14T11:17:03.000Z - 1 year ago

Immuron Ltd at Emerging Growth Virtual Conference Transcript

Immuron Plans Phase 2 Trial for IMM-529 following FDA review

Thu, 05 Sep 2024 11:54:00 -0400 - 1 year ago

Immuron Plans Phase 2 Trial for IMM-529 following FDA review

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Tue, 20 Aug 2024 07:00:00 -0400 - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®

Fri, 16 Aug 2024 06:00:00 -0400 - 1 year ago

Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®

Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference

Thu, 15 Aug 2024 18:14:00 -0400 - 1 year ago

Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference

Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect

Wed, 07 Aug 2024 06:00:00 -0400 - 1 year ago

Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect

Immuron requests pre-IND meeting for IMM-529 with FDA filing

Tue, 02 Jul 2024 06:00:00 -0400 - 1 year ago

Immuron requests pre-IND meeting for IMM-529 with FDA filing

Immuron Board Changes

Fri, 31 May 2024 06:00:00 -0400 - 2 years ago

Immuron Board Changes

Immuron CEO Steven Lydeamore to present at Peak Sky High

Fri, 31 May 2024 06:00:00 -0400 - 2 years ago

Immuron CEO Steven Lydeamore to present at Peak Sky High

Immuron Limited to Present at the Emerging Growth Conference

Tue, 07 May 2024 06:00:00 -0400 - 2 years ago

Immuron Limited to Present at the Emerging Growth Conference

Immuron Director Resignation

Fri, 03 May 2024 06:00:00 -0400 - 2 years ago

Immuron Director Resignation

Immuron to host Live Virtual Event

Mon, 15 Apr 2024 06:00:00 -0400 - 2 years ago

Immuron to host Live Virtual Event

Immuron Travelan® sales continued strong growth

Wed, 10 Apr 2024 06:00:00 -0400 - 2 years ago

Immuron Travelan® sales continued strong growth

Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US

Thu, 07 Mar 2024 06:00:00 -0500 - 2 years ago

Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US

Immuron Presentation Australian Biologics Festival 2024

Feb 21, 2024, 6:00 AM EST - 2 years ago

Immuron Presentation Australian Biologics Festival 2024

Immuron achieves record Travelan® sales

Feb 13, 2024, 6:00 AM EST - 2 years ago

Immuron achieves record Travelan® sales

Immuron CEO, Steven Lydeamore Investor Webinar Presentation

Feb 8, 2024, 6:00 AM EST - 2 years ago

Immuron CEO, Steven Lydeamore Investor Webinar Presentation

Immuron achieves record half yearly Travelan® sales

Jan 16, 2024, 6:00 AM EST - 2 years ago

Immuron achieves record half yearly Travelan® sales

Immuron Clinical Trials Update

Dec 22, 2023, 6:00 AM EST - 2 years ago

Immuron Clinical Trials Update

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Dec 4, 2023, 6:00 AM EST - 2 years ago

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Immuron CEO Steven Lydeamore Investor Webinar Presentation

Nov 13, 2023, 6:00 PM EST - 2 years ago

Immuron CEO Steven Lydeamore Investor Webinar Presentation

Immuron CEO Steven Lydeamore presented at AusBioInvest

Oct 30, 2023, 7:21 AM EDT - 2 years ago

Immuron CEO Steven Lydeamore presented at AusBioInvest

Immuron Announces Travelan® Clinical Study Cohort 2 commences

Oct 18, 2023, 6:00 AM EDT - 2 years ago

Immuron Announces Travelan® Clinical Study Cohort 2 commences

Immuron achieves record quarterly Travelan® sales

Oct 11, 2023, 6:00 AM EDT - 2 years ago

Immuron achieves record quarterly Travelan® sales

Immuron Limited Announces Participation in the LD Micro Main Event XVI

Sep 18, 2023, 7:30 AM EDT - 2 years ago

Immuron Limited Announces Participation in the LD Micro Main Event XVI

Immuron achieves record monthly Travelan® sales

Sep 13, 2023, 6:00 AM EDT - 2 years ago

Immuron achieves record monthly Travelan® sales

Immuron CEO, Steven Lydeamore to present at H.C. Wainwright

Sep 11, 2023, 6:00 AM EDT - 2 years ago

Immuron CEO, Steven Lydeamore to present at H.C. Wainwright

Immuron to present at the Military Health System Research Symposium

Aug 14, 2023, 6:00 AM EDT - 2 years ago

Immuron to present at the Military Health System Research Symposium

t_baggin_u
t_baggin_u Apr. 17 at 10:29 AM
$IMRN https://www.globenewswire.com/news-release/2026/04/17/3276005/37134/en/Immuron-Double-Digit-3Q-Sales-Growth.html
0 · Reply
t_baggin_u
t_baggin_u Apr. 17 at 5:13 AM
$IMRN https://investors.immuron.com.au/announcements/7494849
0 · Reply
DravenHunt
DravenHunt Apr. 13 at 3:10 PM
$IMRN Severe underperformance vs market & peers
0 · Reply
DravenHunt
DravenHunt Apr. 13 at 3:07 PM
$IMRN Extremely weak technical trend..
0 · Reply
UltimateRampageBulls
UltimateRampageBulls Mar. 24 at 10:51 PM
Actually a good group of bulls below, they actually jumped in to some runners early💎 Check them out, Cool free group 👇🔥 Been swinging some $NAK $RZLT $IMRN $ADGM too
0 · Reply
peepthestamp
peepthestamp Mar. 6 at 8:23 PM
$IMRN
0 · Reply
Baseball89
Baseball89 Mar. 3 at 12:32 PM
$EHTH $IMRN keep watch. Profitable yr after yr.
0 · Reply
Baseball89
Baseball89 Feb. 27 at 5:51 PM
$BDSX $NCNA & $IMRN keep watch.Sleeping giant!!!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 27 at 1:58 AM
$IMRN RSI: 57.17, MACD: -0.0454 Vol: 0.07, MA20: 0.78, MA50: 0.87 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Baseball89
Baseball89 Feb. 23 at 11:02 PM
$IMRN This could reach $80-$100 soon. Keep watch.
0 · Reply
LeonCleland213
LeonCleland213 Feb. 18 at 12:49 PM
$IMRN Biotech with long development horizon; dilution risk persistent.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 17 at 6:42 PM
$IMRN Current Stock Price: $0.74
0 · Reply
riskalex
riskalex Feb. 17 at 8:13 AM
$IMRN Pre-revenue biotech; early-stage pipeline
0 · Reply
Baseball89
Baseball89 Feb. 10 at 1:02 PM
$PHIO $IMRN ---keep watch.
0 · Reply
Baseball89
Baseball89 Feb. 10 at 12:05 PM
$LIMN $IMRN - profitable,low float,Travelan, US military. Keep watch.
0 · Reply
Baseball89
Baseball89 Feb. 10 at 11:11 AM
$IMRN let's get this one trending. Low float. Profitable year after year. PT $20
0 · Reply
peepthestamp
peepthestamp Jan. 26 at 7:34 PM
$IMRN
0 · Reply
Emerging_Growth_Research
Emerging_Growth_Research Jan. 23 at 5:54 PM
$IMRN Emerging Growth Research releases a flash report on $IMRN with a $3.50 price target. The report can be viewed here: https://emerginggrowth.com/wp-content/uploads/2026/01/Immuron-Flash-Report-2026-01-22.pdf
0 · Reply
AlertsAndNews
AlertsAndNews Jan. 19 at 8:33 PM
$IMRN Immuron Reports Continued Sales Growth Global H1 sales reached AUD$4.2M, up 5% YoY, while Q2 sales rose 11% QoQ to AUD$2.2M. Australia delivered the strongest performance, with H1 sales up 13% YoY and Q2 up 11% QoQ, supported by the local launch of ProIBS®. U.S. sales increased 17% YoY in H1 and 8% QoQ in Q2, while Canada saw a sharp sequential rebound despite weaker year-over-year results.
0 · Reply
Rasto2020
Rasto2020 Jan. 13 at 4:57 PM
$IMRN did you guys take it ? 17% gain so far
2 · Reply
DarknessAWAITz
DarknessAWAITz Jan. 13 at 4:33 PM
$IMRN amazing DD behind this ticker. Just do a few mins of research and you will see the potential,
1 · Reply
StockfatherOG
StockfatherOG Jan. 13 at 3:35 PM
$IMRN news any day. Good start to the week.
0 · Reply